Cerebral & Done / Online Mental Health Platform DEA Prescription Fraud Class Action

Cerebral Inc. and Done Global Inc. were among the fastest-growing telehealth platforms of the COVID-19 era, advertising quick, easy access to ADHD diagnoses and stimulant prescriptions via app-based consultations. This class action, and parallel DOJ and DEA investigations, allege that both companies systematically pressured clinicians to diagnose ADHD and prescribe Schedule II controlled substances—including amphetamine salts (Adderall) and methylphenidate (Ritalin)—to patients without adequate clinical evaluation, driven by subscription revenue growth targets. Internal communications allegedly showed executives setting prescription rate quotas and penalizing clinicians who did not prescribe at sufficient rates.

Consumer plaintiffs allege that Cerebral and Done engaged in deceptive advertising, misrepresented the quality and rigor of their clinical evaluations, and exposed patients to the risks of stimulant dependency and adverse cardiovascular events. The DOJ launched a criminal investigation into Cerebral in 2022, and the company subsequently exited the stimulant prescribing business. Class members allege they paid subscription fees for a medically negligent and fraudulent service that endangered their health, and seek compensatory damages, refunds, and injunctive relief to reform telehealth prescribing practices for controlled substances.